CD274 and non-small cell lung carcinoma: Currently, three agents (pembrolizumab [Keytruda, Merck, Kenilworth, NJ, USA], nivolumab [Opdivo, Bristol-Myers Squibb, New York, NY, USA], and atezolizumab [Tecentriq, Genentech/Roche, South San Francisco, CA, USA]) have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of PD-L1-positive NSCLC.